OverviewSuggest Edit

Elanco develops, manufactures, and markets products for companion and food animals. The сompany provides products and knowledge services to improve animal health and food-animal production. It offers companion animal disease prevention products, such as parasiticide products; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

TypePublic
Founded1954
HQGreenfield, US
Websiteelanco.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Dec 2018)5,780
Revenue (FY, 2018)$3.1 B
Share Price (Jul 2020)$22.7 (+3%)
Cybersecurity ratingBMore

Key People/Management at Elanco

Jeffrey N. Simmons

Jeffrey N. Simmons

President, CEO
Julie Lawless

Julie Lawless

Senior Vice President, Corporate Affairs and Administration
Ramiro M. Cabral

Ramiro M. Cabral

Executive Vice President, Elanco International
Aaron Schacht

Aaron Schacht

Executive Vice President, Innovation, Regulatory and Business Development
Jacques Zimmowitch

Jacques Zimmowitch

Senior Vice President, Global Quality
Sarena Lin

Sarena Lin

Executive Vice President, Global Marketing, Corporate Strategy & Transformation
Show more

Elanco Office Locations

Elanco has offices in Greenfield, DNN, Melrose Park, Wien and in 28 other locations
Greenfield, US (HQ)
2500 Innovation Way
Greenfield, US
2500 Innovation Way
DNN, AR
piso 12, Tronador 4890
Melrose Park, AU
112 Wharf Rd
Wien, AT
Gebäude G, Am Europl. 2
Antwerpen, BE
Plantin en Moretuslei 1a
Show all (42)

Elanco Financials and Metrics

Elanco Revenue

Elanco's revenue was reported to be $3.07 b in FY, 2018
USD

Revenue (Q1, 2020)

657.7m

Gross profit (Q1, 2020)

325.0m

Gross profit margin (Q1, 2020), %

49.4%

Net income (Q1, 2020)

(49.1m)

Market capitalization (13-Jul-2020)

9.0b

Closing stock price (13-Jul-2020)

22.7

Cash (31-Mar-2020)

1.2b

EV

9.9b
Elanco's current market capitalization is $9 b.
Annual
USDFY, 2018FY, 2019

Revenue

3.1b

Cost of goods sold

1.6b1.5b

Gross profit

1.5b

Gross profit Margin, %

49%
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

761.1m731.1m781.6m771.3m657.7m

Cost of goods sold

369.8m343.8m356.0m360.4m332.7m

Gross profit

391.3m387.3m425.6m410.9m325.0m

Gross profit Margin, %

51%53%54%53%49%
Annual
USDFY, 2018FY, 2019

Cash

474.8m345.1m

Accounts Receivable

651.8m816.9m

Prepaid Expenses

113.9m87.4m

Inventories

1.0b1.1b
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

300.0m272.1m385.1m309.2m1.2b

Accounts Receivable

606.1m684.1m757.2m758.3m676.8m

Prepaid Expenses

123.2m114.8m102.3m132.1m

Inventories

1.0b1.0b1.1b
Annual
USDFY, 2018FY, 2019

Net Income

86.5m67.9m

Depreciation and Amortization

296.0m314.5m

Inventories

(20.1m)(33.1m)

Accounts Payable

116.1m(29.2m)
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

70.1m31.5m67.4m77.4m(49.1m)

Depreciation and Amortization

222.3m83.1m152.4m231.1m81.5m

Cash From Operating Activities

347.8m5.6m58.2m97.8m4.3m

Purchases of PP&E

(74.3m)(28.0m)(51.8m)(12.6m)
USDQ3, 2018

Financial Leverage

1.8 x
Show all financial metrics

Elanco Acquisitions / Subsidiaries

Company NameDateDeal Size
Aratana TherapeuticsApril 26, 2019$245 m
Janssen Animal Health BVBAJuly 07, 2011

Elanco Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Elanco Online and Social Media Presence

Embed Graph

Elanco News and Updates

Elanco Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco Animal Health Incorporated To Contact The Firm

NEW YORK, NY - (NewMediaWire) - June 26, 2020 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE:ELAN) of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securiti…

Elanco Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco Animal Health Incorporated To Contact The Firm

NEW YORK - (NewMediaWire) - June 17, 2020 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE:ELAN) of the July 20, 2020 deadline to seek the role of lead plaintiff in a federal securities c…

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Elanco Animal Health Incorporated Investors of Important July 20 Deadline in Securities Class Action - ELAN

NEW YORK, June 4, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Elanco Animal Health Incorporated (NYSE: ELAN) between January 10, 2020 and May 6, 2020, inclusive (the "Class Period") of the important July 20, 2020 lead...

Elanco Animal Health's stock falls after downbeat profit outlook

Shares of Elanco Animal Health Inc. fell 0.9% in premarket trading Friday after the company provided 2020 profit guidance that was below analyst expectations. The company said it expects net earnings per share of 4 cents to 16 cents in 2020 and adjusted EPS, which excluding non-recurring items, of …

Elanco announces layoff of 250 workers

Elanco Animal Health Inc. , which went public a year ago, on Monday said it plans to lay off 250 workers to save $12 million in 2020. The Greenfield, Ind.-based company previously announced job cuts and a $37 million restructuring charge in December 2018. In February, Eli Lilly & Co. said it wo…

Global Feed Anticoccidials Market Report 2019-2025 Top Key Players- Elanco Animal Health , Huvepharma, Phibro Animal and more...

A new market study, titled “Global Feed Anticoccidials Market Insights, Forecast to 2025”, has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

Elanco Frequently Asked Questions

  • When was Elanco founded?

    Elanco was founded in 1954.

  • Who are Elanco key executives?

    Elanco's key executives are Jeffrey N. Simmons, Julie Lawless and Ramiro M. Cabral.

  • How many employees does Elanco have?

    Elanco has 5,780 employees.

  • Who are Elanco competitors?

    Competitors of Elanco include Zoetis, Merck Animal Health USA and Meditop Pharmaceutical.

  • Where is Elanco headquarters?

    Elanco headquarters is located at 2500 Innovation Way, Greenfield.

  • Where are Elanco offices?

    Elanco has offices in Greenfield, DNN, Melrose Park, Wien and in 28 other locations.

  • How many offices does Elanco have?

    Elanco has 42 offices.